Adam Marc Apton
Levi & Korsinsky, LLP
- Address of record
- 33 Whitehall Street, 27th Floor, New York, NY 10004, 212-363-7500
- aapton@zlk.com
- Phone
- (212) 363-7500
Contact details as filed with the court in the cases below.
Case history
Publicly tracked matters where this attorney is listed as counsel.
Masimo Securities Settlement
Masimo Corporation allegedly made misleading statements or omissions regarding its publicly traded common stock. Shareholders claim they were damaged by purchasing or acquiring the stock during the class period.
- Claim deadline
- April 28, 2026
- Represents
- Sergio Vazquez
Proterra Inc. Securities Litigation Settlement
Proterra Inc. and its defendants are settling securities litigation brought by shareholders who claim they were harmed by alleged misconduct related to Proterra's business combination with ArcLight Clean Transition Corp. and subsequent stock sales. The defendants are paying $29 million to resolve all claims without admitting wrongdoing.
- Settlement fund
- $29M
- Claim deadline
- August 29, 2025
- Represents
- Jeremy Villanueva, Tanya Tirado, William E. Zinn, Raymond H. Quick, Cyress Jam, Luong Du
ImmunityBio Inc. Securities Litigation Settlement
Lead Plaintiff alleges that ImmunityBio, Inc. and its executives made false or misleading statements regarding the company's securities during the class period. The defendants have agreed to settle the litigation for $10,500,000 in cash without admitting wrongdoing.
- Settlement fund
- $10.5M
- Claim deadline
- July 7, 2025
- Represents
- Timothy L. Van Eman
Arqit Quantum Inc. Securities Settlement
Arqit Quantum Inc. (formerly Centricus Acquisition Corp.) and its executives allegedly made false or misleading statements and omissions regarding the company in connection with a merger and the offering of securities to investors. Defendants deny all wrongdoing and liability.
- Settlement fund
- $7M
- Claim deadline
- June 22, 2026
- Represents
- Erwin Jay Lack, Patrick L. Hagemeister
Katapult Securities Litigation Settlement
Katapult Holdings and its executives allegedly made materially false and misleading statements about the company's financial prospects and omitted critical information in connection with a business combination with FinServ Acquisition Corp., causing the price of Katapult securities to be artificially inflated. The settlement resolves claims that investors suffered damages after the true facts were revealed.
- Settlement fund
- $2.5M
- Claim deadline
- Represents
- Devang Patel
FibroGen, Inc. Securities Litigation Settlement
FibroGen and its executives allegedly misrepresented the safety profile and Phase III trial results of its anti-anemia drug Roxadustat in filings with the FDA. Investors claim the company's stock price was artificially inflated by these false statements and declined when the truth was revealed. The defendants deny all allegations of wrongdoing.
- Settlement fund
- $28.5M
- Claim deadline
- Represents
- George Assad
Tricida Securities Settlement
Tricida, Inc. and defendant Gerrit Klaerner are alleged to have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The defendant denies all claims and wrongdoing. The settlement resolves these allegations without admission of liability.
- Settlement fund
- $14.3M
- Claim deadline
- October 1, 2025
- Represents
- Nancy Catherine Wang
Turquoise Hill Securities Litigation Settlement
Rio Tinto and two executives made material misrepresentations and omissions about Turquoise Hill Resources' business, including statements about the development of the Oyu Tolgoi mine in Mongolia and related delays and cost overruns. Investors alleged they were damaged by these misstatements during the class period.
- Settlement fund
- $138.8M
- Claim deadline
- September 24, 2025
- Represents
- Chang Pin Lin
Rain Oncology Securities Settlement
Rain Oncology and its executives allegedly made misrepresentations and omissions about the company's development and commercialization of milademetan between April 2021 and May 2023. The defendants violated federal securities laws by making false or misleading statements in public filings. The defendants deny any wrongdoing.
- Settlement fund
- $7.3M
Wilhite v. Expensify Securities Settlement
Expensify, Inc. and underwriter defendants allegedly made misrepresentations and omissions of material fact in Expensify's registration statement filed in connection with its November 10, 2021 initial public offering. Defendants admit no wrongdoing but agreed to settle to avoid the costs and uncertainties of further litigation.
- Settlement fund
- $9.5M
“Recovery” and “exposure” refer to total disclosed settlement funds in associated cases, not money personally won or lost by an attorney. Settlements generally resolve disputed allegations without a finding that either side won. Data comes from public court dockets and may be incomplete.